NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
NeoImmuneTech
Washington University School of Medicine
NeoImmuneTech
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)